Novel Concepts Medical Groundbreaking Anti-Viral Medicine Successfully Disrupted COVID-19 Spike Protein Attachment into Host Cells, Intended to Stop Omicron

Novel Concepts Medical, founded by Rachel Alkalay, PhD, and based in Tel Aviv, is delighted to announce the successful testing of its plant-based formulations for the treatment of SARS-CoV-2, the virus responsible for the COVID-19 pandemic.

The testing methodology was devised by Dr. Alkalay, who is the inventor of these formulations.

The testing, led by Tracey Campbell, PhD, was carried out by the Centre for Microbial Chemical Biology at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University in Ontario, Canada.

The first test demonstrated the ability to disrupt the SARS-CoV-2 spike-ACE2 receptor interaction, which is a therapeutic target for COVID-19. Disruption of this interaction will prevent viral entry into cells.

The second test demonstrated the ability to disrupt the TMPRSS2, which represents an additional therapeutic target for COVID-19.

The third test demonstrated anti-viral activity in cell culture.

The testing program concluded: “The NCM formulations act on multiple targets required for SARS CoV-2 infection. This has been demonstrated by in vitro enzyme testing and cell culture assays with a surrogate human coronavirus. This data suggests that these formulations are potential candidates for treatment of SARS CoV-2 infections.”

Dr. Alkalay said that her invention is unique because, according to her research, it is the first in the world to treat the attachment of sugar residues to proteins in the SARS-CoV-2 spike glycoproteins, which play essential roles in the virus’s attachment, fusion, and entry into the host cells. Therefore, due this novel scientific finding, it may very potentially STOP OMICRON as well as other mutations and other viruses, such as influenza and HIV. In addition, it is the first plant-based drug in the world that demonstrated recovery within 48 hours in preliminary case studies, as well as significant improvements in every Long COVID-19 symptom tested in those cases, without any side effects.

The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours. Specifically, all volunteers with positive PCR tests had negative PCR tests within 48 hours of taking NCM’s formulations, with no side effects. These case studies also demonstrated significant improvement of numerous Long COVID-19 symptoms, including fatigue, headaches, loss of taste and smell, fever, throat ache, and memory loss.

Earlier pre-clinical studies, which were published in January 2021, showed the company has successfully decreased the spike protein in just six hours. For more information about the company, its lab results, or collaborating with the company for clinical testing, please contact Dr. Rachel Alkalay by using her LinkedIn.

Share

Share on facebook
Share on linkedin
Share on twitter
Share on pinterest